XYone Therapeutics, Inc. ("XYone"), a clinical-stage biotechnology company, announced that the first patient has been dosed in the first-in-human Phase 1b/2 clinical trial of XYA02(also known as ...
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceutical company, will invest $2 billion in Summit Therapeutics Inc ...
India is among 19 jurisdictions eligible for zero tariffs on certain specialty medicines under the US Section 232 exemption, ...
AstraZeneca makes a $2 billion equity investment in Summit Therapeutics to accelerate the development of cancer drug ...
The US will exempt select Indian specialty drugs and their ingredients from a new 100% pharma tariff. Here’s what products ...
AstraZeneca will invest $2 billion in Summit Therapeutics convertible preferred shares, with Summit stock up more than 17% ...
The equity investment comes alongside a deal to test Summit’s ivonescimab alongside potentially many AstraZeneca drugs — but ...
AstraZeneca invests £1.5bn into US firm Summit for cancer drug tie-up - The firms will collaborate on Summit’s experimental ...
Washington, DC [US], September 29 (ANI): In a major development for international trade, Washington has announced that select speciality medications and related components originating from India and ...
6hon MSN
Summit Therapeutics soars nearly 20% after AstraZeneca bets $2 billion on cancer drug Ivonescimab
Shares of Summit Therapeutics Inc. (NASDAQ: SMMT) surged about 20% premarket on Tuesday after AstraZeneca Plc (NYSE: AZN) ...
Sept 28 (Reuters) - Summit Therapeutics said on Monday that British drugmaker AstraZeneca would invest $2 billion in the ...
AstraZeneca ( AZN) has agreed to make a $2 billion strategic equity investment in Summit Therapeutics ( SMMT) while launching a clinical collaboration aimed at advancing new cancer treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results